Portal de investigação
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2019
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norgevicus: a categorization proposal
Ferreira Duarte, M; (...); Duarte Ara?jo, M.
Article. 10.1538/expanim.20-0113. 2021
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
Review. 10.1177/17562848221142673. 2022
A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective study
Meeting Abstract. 2023
Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines
Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study
Abreu, C; (...); Magro, F
Article. 10.3390/vaccines11030703. 2023
Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?
Ministro, P; (...); Magro, F.
Article. 10.14309/ctg.0000000000000309. 2021
Aminosalicylates and COVID-19: Facts or Coincidences?
Magro, F., Dias, C., Morato, M.
Letter. 10.1053/j.gastro.2020.05.092. 2021
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
Article. 10.1111/eci.14283. 2024
Analysis of clinical features associated with favourable outcomes from ustekinumab treat-totarget strategy in Crohn's Disease patients in the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab075.039. 2021
Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis
Article. 10.1111/jgh.16541. 2024
Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations
Meeting Abstract. 2023
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Article. 10.1093/ibd/izac061. 2023
Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review
Review. 10.3390/ijms252312852. 2024
Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease
Meeting Abstract. 2022
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
Meeting Abstract. 10.1136/gutjnl-2022-BSG.74. 2022
Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''
Editorial Material. 10.1016/j.dld.2023.12.006. 2024
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
Article. 10.1093/ibd/izae162. 2024
Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study
Meeting Abstract. 2024
Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties
Couto, MR; (...); Martel, F.
Article. 10.1016/j.yexcr.2023.113670. 2023
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
D'Amico, F; (...); Danese, S
Review. 10.1016/j.autrev.2021.102849. 2021
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
Meeting Abstract. 2021
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
Article. 10.1159/000525206. 2023
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
Meeting Abstract. 2022
CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL
Meeting Abstract. 2021
Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 2020
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Article. 10.1111/apt.17751. 2024
Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine
Editorial Material. 10.20344/amp.21371. 2024
Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis
Magro, F; (...); Peyrin-Biroulet, L
Review. 10.1093/ecco-jcc/jjaa176. 2021
Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels
Magro, F; (...); Carneiro, F
Article. 10.1093/ecco-jcc/jjz123. 2020
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
Article. 10.1002/ueg2.12492. 2024
Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis
Magro, F; (...); Carneiro, F
Article. 10.1093/ecco-jcc/jjaa010. 2020
Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies
Meeting Abstract. 2022
Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis
Magro, F; (...); Moreira, PL
Review. 10.1177/17562848221092754. 2022
Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis
Magro, F; (...); Moreira, P
Review. 10.1002/ueg2.12183. 2022
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Ma, C; (...); Jairath, V
Article. 10.1053/j.gastro.2022.06.068. 2022
COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology
Magro, F.; (...); Siau, K
Review. 10.1002/ueg2.12115. 2021
COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives
Editorial Material. 10.1093/ecco-jcc/jjac042. 2022
CROHN'S DISEASE ILEAL B3 WITH STENOSIS HAS A DISTINCT HISTOPATHOLOGICAL SCORING AND PROFILE WHEN COMPARED TO B3 WITHOUT STENOSIS AND B2 PHENOTYPES
Sousa, HT; (...); Magro, F
Meeting Abstract. 2020
CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2
Meeting Abstract. 2020
Changing paradigms in management of inflammatory bowel disease
Editorial Material. 10.1002/ueg2.12347. 2022
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
Schreiber, S; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad130. 2023
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Review. 10.1002/ueg2.12671. 2024
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.1002/ueg2.12283. 2022
Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper
Feakins, R; (...); Rosini, F
Article. 10.1093/ecco-jcc/jjad142. 2023
Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
Meeting Abstract. 2024
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Article. 10.1093/ibd/izae204. 2024
Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
Peyrin-Biroulet, L; (...); Kubassova, O
Meeting Abstract. 2023
DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES
Meeting Abstract. 2023
Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study (vol 12, pg 1104, 2021)
Charbit-Henrion, F; (...); Cerf-Bensussan, N
Correction. 10.1093/ecco-jcc/jjaa164. 2021
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey
Parigi, TL; (...); Danese, S
Letter. 10.1016/S2468-1253(22)00085-1. 2022
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Parigi, TL; (...); Danese, S
Review. 10.1016/S2468-1253(23)00154-1. 2023
Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions
Gomes, SF; (...); Magro, F
Article. 10.1515/cclm-2023-0139. 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
D'Amico, F; (...); Danese, S
Review. 10.1093/ibd/izad159. 2023
Do Neutrophils Contribute to Development of Crohn's Disease and Ulcerative Colitis?
Magro, F, Estevinho, MM
Editorial Material. 10.1016/j.cgh.2020.01.032. 2020
Dose optimisation for Loss of Response to Vedolizumab - Pharmacokinetics and Immune Mechanisms
Ungar, B; (...); Ben Horin, S
Article. 10.1093/ecco-jcc/jjab067. 2021
Drug Prescribing Analysis: The Burden Of Orphan Drugs In A Tertiary Hospital Budget
Meeting Abstract. 2023
Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Meeting Abstract. 2024
ECCO Governing Board European Crohn's and Colitis Organisation - ECCO, Ungargasse 6/13, A-1030 Vienna, Austria
Letter. 10.1093/ecco-jcc/jjab225. 2022
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Kucharzik, T; (...); Vavricka, S
Editorial Material. 10.1093/ecco-jcc/jjab052. 2021
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Torres, J; (...); Fiorino, G
Article. 10.1093/ecco-jcc/jjz180. 2020
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
Adamina, M; (...); Wildt, S
Article. 10.1093/ecco-jcc/jjz187. 2020
ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology
Magro, F; (...); Feakins, R
Article. 10.1093/ecco-jcc/jjac006. 2022
ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology
Magro, F.; (...); Feakins, R
Article. 10.1093/ecco-jcc/jjaa110. 2020
Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study
Estevinho, MM, Magro, F
Editorial Material. 10.1111/apt.17543. 2023
Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab075.034. 2021
Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)
Cosme, D., Soares-da-Silva, P., Magro, F.
Correction. 10.1152/ajpgi.00139.2023_COR. 2023
Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells
Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando
Article. 10.1152/ajpgi.00139.2022. 2022
EFFECT OF UPADACITINIB ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE IN THE PHASE 3, U-EXCEL, U-EXCEED, AND U-ENDURE STUDIES
Meeting Abstract. 2023
Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Meeting Abstract. 2023
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study
Albshesh, A; (...); Kopylov, U
Article. 10.3390/jcm10132914. 2021
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Article. 10.1016/j.cgh.2023.11.010. 2024
Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials
Meeting Abstract. 2024
Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension
Meeting Abstract. 2024
Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial
Peyrin-Biroulet, L; (...); Danese, S
Meeting Abstract. 2022
EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN'S DISEASE: RESULTS FROM THE STARDUST TRIAL
Meeting Abstract. 2022
Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Loftus, E; (...); Lichtenstein, G
Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023
ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST INTERIM ANALYSIS
Meeting Abstract. 2020
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Guillo, L; (...); Peyrin-Biroulet, L
Review. 10.1016/S2468-1253(21)00297-1. 2022
Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis
Letter. 10.1016/j.cgh.2021.08.003. 2022
European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations
Review. 10.1177/2050640620951905. 2021
Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review (vol 14, pg 688, 2020)
Magro, F; (...); Peyrin-Biroulet, L
Correction. 2021
Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review
Estevinho, MM; (...); Magro, F
Review. 10.1016/j.cgh.2019.08.063. 2020
Fecal Calprotectin Levels, C-Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study
Meeting Abstract. 10.14309/01.ajg.0000592828.44710.08. 2019
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Pinto Lopes, P; (...); Magro, F.
Article. 10.14309/ctg.0000000000000320. 2021
Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue
De Sousa, HT, Gullo, I, Magro, FERNANDO
Letter. 10.1016/j.cgh.2022.06.023. 2023
Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
Meeting Abstract. 2024
Gastroenterological features of COVID-19 and the role of the United European Gastroenterology Journal
Magro, F, Drenth, JPH
Editorial Material. 10.1177/2050640620926832. 2020
Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis
Pereira, MS; (...); Pinho, SS
Article. 10.14309/ctg.0000000000000166. 2020
Gut bacterial microbiome composition and statin intake-A systematic review
Dias, AM; (...); Magro, F
Review. 10.1002/prp2.601. 2020
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis
Magro, F; (...); Santiago, M
Review. 10.1002/ueg2.12366. 2023
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study
Burisch, J; (...); Odes, S
Article. 10.1016/S2468-1253(20)30012-1. 2020
Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Surgical Intervention versus Immunomodulatory Therapy
Portela, F; (...); Magro, F
Article. 10.1159/000501823. 2020
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Review. 10.1080/17474124.2024.2326838. 2024
Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease
Meeting Abstract. 2022
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Magro, F.; (...); Carneiro, F.
Article. 10.1016/j.cgh.2020.09.017. 2021
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure
Chateau, T; (...); Peyrin-Biroulet, L
Review. 10.14309/ajg.0000000000000437. 2020
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study
Magro, F; (...); Dias, CC
Article. 10.1002/ueg2.12420. 2023
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Peyrin-Biroulet, L; (...); Beaugerie, L
Article. 10.1016/j.cgh.2022.09.018. 2023
Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype
de Sousa, HT; (...); Magro, F
Article. 10.14309/ctg.0000000000000330. 2021
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis
Review. 10.1093/ibd/izac203. 2023
Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn's disease
Meeting Abstract. 10.1136/gutjnl-2023-BSG.370. 2023
Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
Meeting Abstract. 10.1093/ecco-jcc/jjab076.519. 2021
Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease
Meeting Abstract. 2021
Impact of mirikizumab therapy on histological measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
Meeting Abstract. 2022
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Review. 10.1016/j.autrev.2023.103504. 2024
Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
Santiago, M; (...); Magro, F
Article. 10.14309/ctg.0000000000000481. 2022
Inflammation of the appendix in ulcerative colitis - Does it have a predictive value?
Magro, F, Estevinho, MM, Feakins, R
Editorial Material. 10.1002/ueg2.12181. 2021
Inflammatory Bowel Disease - Non-biological treatment
Magro, F; (...); Estevinho, MM
Review. 10.1016/j.phrs.2020.105075. 2020
Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?
Review. 10.2174/1389450122666210203193817. 2021
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce
Magro, F; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjaa160. 2020
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce (vol 14, pg s798, 2020)
Correction. 2021
Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence
Santiago, M; (...); Dias, CC
Article. 10.14309/ctg.0000000000000227. 2020
Infrared furnace for in situ neutron single-crystal diffraction studies in controlled gas atmospheres at high temperatures
Article. 10.1107/S1600576721003198. 2021
Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis
Ferreira-Duarte, M; (...); Morato, M
Article. 10.3390/ijms22094836. 2021
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.3390/medicina59010183. 2023
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
D'Amico, F; (...); Peyrin-Biroulet, L
Article. 10.1002/ueg2.12069. 2021
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Olivera, PA; (...); Peyrin-Biroulet, L
Article. 10.1038/s41575-021-00492-8. 2021
Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis
Article. 10.3390/biomedicines11123137. 2023
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Caron, B; (...); Peyrin-Biroulet, L
Article. 10.1016/j.cgh.2022.02.032. 2022
Is Faecal Calprotectin Important in Detecting Silent Gut Inflammation in Seronegative Arthropathies?
Magro, F, Estevinho, MM
Editorial Material. 10.1093/ecco-jcc/jjaa011. 2020
Is tofacitinib a game-changing drug for ulcerative colitis?
Magro, F, Estevinho, MM
Review. 10.1177/2050640620935732. 2020
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Review. 10.3390/jcm12031142. 2023
Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results
Meeting Abstract. 2024
Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells
Cosme, D, soares-da-silva, p, Magro, F
Article. 10.1152/ajpcell.00208.2022. 2023
Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study
Magro, F.; (...); Carneiro, F.
Article. 10.1093/ecco-jcc/jjz071. 2019
Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention
Ungar, B; (...); Ben-Horin, S
Meeting Abstract. 2020
LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL SHORTENING ARE NOT PREDICTIVE OF SUCCESS OF THE INTERVENTION
Meeting Abstract. 2020
Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?
Article. 10.1093/jcag/gwad034. 2023
Microbiota therapeutics for inflammatory bowel disease: the way forward
Article. 10.1016/S2468-1253(23)00441-7. 2024
Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease
Couto, MR; (...); Martel, F.
Review. 10.1016/j.phrs.2020.104947. 2020
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
Louis, E; (...); Travis, SP
Article. 10.1136/bmjgast-2021-000853. 2022
Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis
Magro, F, Estevinho, MM
Editorial Material. 10.1177/2050640619878588. 2019
Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
Meeting Abstract. 2024
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group
D'Amico, F; (...); Peyrin-Biroulet, L
Review. 10.1016/j.dld.2019.11.004. 2020
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Article. 10.1080/00365521.2021.2015801. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Fernandes, BM; (...); Bernardes, J.
Article. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Article. 2022
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
Editorial Material. 10.1093/ecco-jcc/jjae136. 2024
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
Review. 10.1111/apt.18315. 2024
Newborn Congenital Abnormalities and Inflammatory Bowel Disease: Unveiling an Unexplored Relationship
Magro, F, Estevinho, MM
Editorial Material. 10.1093/ecco-jcc/jjaa026. 2020
Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision
Gaspar, RS; (...); Feio, J
Review. 10.3389/fmed.2020.590527. 2020
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Olivera, PA; (...); Peyrin-Biroulet, L
Review. 10.1093/ecco-jcc/jjac133. 2023
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Schreiber, S; (...); Reinisch, W
Review. 10.1007/s12325-021-01990-6. 2022
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022)
Schreiber, S; (...); Reinisch, W
Correction. 10.1007/s12325-022-02082-9. 2022
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
Meeting Abstract. 2021
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Imbrizi, M, Magro, F, Coy, CSR
Review. 10.3390/ph16091272. 2023
Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
Martins, A; (...); de Abreu, CMF
Meeting Abstract. 2023
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
D'Amico, F; (...); Danese, S
Review. 10.1093/ecco-jcc/jjab206. 2022
Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review
Cosme, D; (...); Magro, F
Review. 10.1152/ajpcell.00393.2020. 2021
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
D'Amico, F; (...); Danese, S
Article. 10.3390/jcm12196350. 2023
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
Review. 10.1080/17474124.2024.2397650. 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Article. 10.1093/ecco-jcc/jjae026. 2024
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus
Meeting Abstract. 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Article. 10.1016/j.dld.2024.03.010. 2024
Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis
Meeting Abstract. 2024
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis
Fernandes, SR; (...); Magro, F
Article. 10.1093/ibd/izad272. 2023
Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study
Meeting Abstract. 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study
Article. 10.1002/ueg2.12572. 2024
Prospective study of blood viral load of Epstein-Barr virus, herpes virus type 6 and human parvovirus B19 in Crohn's disease: Does therapy matter?
Abreu, C.; (...); Magro, F
Article. 10.1016/j.jcv.2020.104515. 2020
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
Review. 10.1177/17562848231155987. 2023
Quantifying inflammation and fibrosis through a surgical histopathological score can differentiate ileal Crohn's disease phenotypes and predict postoperative progressive disease
de Sousa, HT; (...); Magro, F
Meeting Abstract. 2020
Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
Rocha, C; (...); Magro, F
Article. 10.1177/1756284820965790. 2020
Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study
Santiago, M; (...); Dias, CC
Article. 10.1177/1756284820923836. 2020
Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
Magro, F, Estevinho, MM
Editorial Material. 10.1002/ueg2.12432. 2023
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Magro, F; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad050. 2023
Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial
Meeting Abstract. 2024
Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in inflammatory Bowel Disease
Pinto Lopes, P; (...); Magro, F.
Article. 10.1093/ibd/izz319. 2020
Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease (izz319) (Jan, 10.1093/ibd/izz319, 2020)
Pinto-Lopes, P; (...); Magro, F
Correction. 10.1093/ibd/izaa058. 2020
Sexual Quality of Life in Inflammatory Bowel Disease: A Multicenter, National-Level Study
Roseira, J; (...); de Sousa, HT
Article. 10.1093/ibd/izz185. 2020
Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language
Article. 10.1186/s12955-021-01698-9. 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Magro, F; (...); Dias, CC
Article. 10.1016/j.cgh.2021.12.004. 2022
SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS
Meeting Abstract. 2022
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab.
Borrega R; (...); Goncalves J
Review. 10.1007/s40259-020-00458-3. 2021
The daily impact of COVID-19 in gastroenterology
Magro, F, Abreu, C, Rahier, JF
Review. 10.1177/2050640620920157. 2020
The degree of bowel remission predicts phenotype progression in Crohn's disease
Article. 10.1002/ueg2.12581. 2024
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Article. 10.5217/ir.2022.00006. 2022
The Impact of SARS-CoV-2 on Inflammatory Bowel Disease
Estevinho, MM, Magro, F
Editorial Material. 10.1159/000508114. 2020
The importance of a Clinical Pharmacology Unit to a Pharmacy and Therapeutics Committee, in a tertiary hospital
Meeting Abstract. 2023
The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients
Meeting Abstract. 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Article. 10.1093/ecco-jcc/jjae014. 2024
The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review
Santiago, M; (...); Magro, F
Review. 10.1093/ibd/izab334. 2022
The Process of Developing a Disease Activity Index in Microscopic Colitis
Article. 10.1093/ecco-jcc/jjab170. 2022
The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review
Melo, F.; (...); Magro, F.
Article. 10.1093/ibd/izaa324. 2021
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study
Burisch, J; (...); Munkholm, P
Article. 10.1177/2050640620945949. 2020
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Article. 10.1016/j.dld.2023.10.027. 2024
Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis
Sousa, P; (...); Magro, F
Review. 10.3390/jcm9072216. 2020
Thiopurines' metabolites levels and drug toxicity: a systematic review and meta-analysis
Sousa, PC; (...); Magro, F
Meeting Abstract. 2020
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
Sousa, P; (...); Magro, F
Article. 10.1016/j.dld.2021.05.038. 2021
Thiopurines: use them or lose them? Results of an international survey
Meeting Abstract. 10.1093/ecco-jcc/jjab076.531. 2021
Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease
Fernandes, SR; (...); Magro, F
Article. 10.1002/ueg2.12497. 2023
Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties (vol 14, pg 743, 2020)
de Sousa, HT; (...); Magro, F
Correction. 2021
Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease
Meeting Abstract. 2024
Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
Article. 10.1002/ueg2.12356. 2023
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Danese, S; (...); Peyrin-Biroulet, L
Article. 10.1016/S2468-1253(21)00474-X. 2022
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study
Article. 10.1002/ueg2.12288. 2022
Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease
Ferreira Duarte, M; (...); Morato, M.
Article. 10.1093/ibd/izaa249. 2020
Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results
Meeting Abstract. 2024
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
Meeting Abstract. 2021
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial
Panés, J; (...); Dignass, A
Article. 10.1002/ueg2.12384. 2023
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab076.425. 2021
Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases
Abreu, C; (...); Magro, F
Article. 10.1097/MEG.0000000000002589. 2023
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
Vermeire, S; (...); Danese, S
Article. 10.1093/ecco-jcc/jjaa027. 2020
Viable Mycobacterium avium subsp. paratuberculosis Colonizes Peripheral Blood of Inflammatory Bowel Disease Patients
Estevinho, MM; (...); Sarmento, A
Article. 10.3390/microorganisms11061520. 2023
